Escande M, David D, Diadema B
Therapie. 1989 May-Jun;44(3):161-5.
In order to evaluate the antihypertensive action of intravenous (i.v.) nicardipine, a calcium channel blocker, we included 28 patients (20 women and 8 men) aged from 71 to 93 years (mean age: 80.4 yrs) poorly controlled by their normal antihypertensive treatment, which had not consisted of a calcium channel blocker. These patients had past histories of a variety of cardiovascular disorders: valve disease (n = 4), disorders of cardiac rhythm (n = 3), paced or unpaced disorders of cardiac conduction (n = 8), and cerebrovascular accident (n = 12). On inclusion, their systolic blood pressure (SBP) was greater than or equal to 180 mmHg and/or their diastolic blood pressure (DBP) greater than or equal to 100 mmHg. Blood pressure recordings (SBP, DBP, MBP) and heart rate (HR) were simultaneously taken every 3 minutes for a period of 140 minutes by an automatic apparatus and a mercury manometer, before and after i.v. administration of nicardipine at 3 increasing dosages, respectively 1.25 mg (20 th min), 2.5 mg (32 th min) and 5 mg (44 th min), each injected over a period of 6 minutes. With a cumulative dose of 8.75 mg nicardipine i.v., the SBP decreased significantly from 192.6 to 138.8 mmHg (p less than 0.001); similarly, the DBP fell from 93.9 to 65.8 mmHg (p less than 0.001) and the MBP from 126.2 to 90.1 mmHg (Hg manometric measurement). In addition, after the final dose of nicardipine, the blood pressure progressively rose to reach levels, by the end of the trial, of 172.1 mmHg (SBP) and 91.1 mmHg (DBP).(ABSTRACT TRUNCATED AT 250 WORDS)
为了评估钙通道阻滞剂静脉注射尼卡地平的降压作用,我们纳入了28例患者(20名女性和8名男性),年龄在71至93岁之间(平均年龄:80.4岁),他们的常规降压治疗效果不佳,且之前未使用过钙通道阻滞剂。这些患者有多种心血管疾病病史:瓣膜病(n = 4)、心律失常(n = 3)、有或无起搏器的心脏传导障碍(n = 8)以及脑血管意外(n = 12)。纳入时,他们的收缩压(SBP)大于或等于180 mmHg和/或舒张压(DBP)大于或等于100 mmHg。在静脉注射尼卡地平前和分别以1.25 mg(第20分钟)、2.5 mg(第32分钟)和5 mg(第44分钟)这3种递增剂量注射后,使用自动仪器和水银血压计每3分钟同时记录一次血压(SBP、DBP、平均动脉压[MBP])和心率(HR),每次注射持续6分钟。静脉注射尼卡地平累积剂量达8.75 mg时,SBP从192.6 mmHg显著降至138.8 mmHg(p < 0.001);同样,DBP从93.9 mmHg降至65.8 mmHg(p < 0.001),MBP从126.2 mmHg降至90.1 mmHg(水银血压计测量)。此外,在最后一剂尼卡地平注射后,血压逐渐上升,到试验结束时达到172.1 mmHg(SBP)和91.1 mmHg(DBP)的水平。(摘要截断于250字)